141 related articles for article (PubMed ID: 21244307)
1. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease.
Hauser RA; Reichmann H; Lew M; Asgharian A; Makumi C; Shulman KJ
Int J Neurosci; 2011 May; 121(5):246-53. PubMed ID: 21244307
[TBL] [Abstract][Full Text] [Related]
2. Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease.
Makumi CW; Asgharian A; Ellis J; Shaikh S; Jimenez T; VanMeter S
Int J Neurosci; 2016; 126(1):30-8. PubMed ID: 25495896
[TBL] [Abstract][Full Text] [Related]
3. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
Lyons KE; Pahwa R
Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
[TBL] [Abstract][Full Text] [Related]
4. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
Tompson D; Oliver-Willwong R
Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
[TBL] [Abstract][Full Text] [Related]
7. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.
Singer C; Lamb J; Ellis A; Layton G;
Mov Disord; 2007 Mar; 22(4):476-82. PubMed ID: 17318839
[TBL] [Abstract][Full Text] [Related]
8. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies.
Onofrj M; Bonanni L; De Angelis MV; Anzellotti F; Ciccocioppo F; Thomas A
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S85-92. PubMed ID: 20123565
[TBL] [Abstract][Full Text] [Related]
9. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
[TBL] [Abstract][Full Text] [Related]
10. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
[TBL] [Abstract][Full Text] [Related]
11. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
Dusek P; Busková J; Růzicka E; Majerová V; Srp A; Jech R; Roth J; Sonka K
Clin Neuropharmacol; 2010 Jul; 33(4):186-90. PubMed ID: 20661025
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease.
Hattori N; Hasegawa K; Sakamoto T
J Clin Pharm Ther; 2012 Oct; 37(5):571-7. PubMed ID: 22390368
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
15. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
16. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
[TBL] [Abstract][Full Text] [Related]
17. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
Hersh BP; Earl NL; Hauser RA; Stacy M
Mov Disord; 2010 May; 25(7):927-31. PubMed ID: 20461810
[TBL] [Abstract][Full Text] [Related]
18. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome.
Garcia-Borreguero D; Grunstein R; Sridhar G; Dreykluft T; Montagna P; Dom R; Lainey E; Moorat A; Roberts J
Sleep Med; 2007 Nov; 8(7-8):742-52. PubMed ID: 17512789
[TBL] [Abstract][Full Text] [Related]
19. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
